449152-75-4

Upstream product

• 107-19-7 propargyl alcohol 
• 2775-87-3 3-N-benzoyluracil 
• 106-96-7 propargyl bromide 
• 98-88-4 benzoyl chloride 

Downstream Products

• 1616268-22-4 (1S,2S)-3-{4-[(3-benzoyl-2,4-dioxopyrimidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1,2-dihydroxypropylphosphonic acid 
• 1616268-19-9 (1S,2S)-dibenzyl 2-benzyloxy-3-{4-[(3-benzoyl-2,4-dioxopyrimidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-hydroxypropylphosphonate 
• 1616268-33-7 (1R,2S)-dibenzyl 2-benzyloxy-3-{4-[(3-benzoyl-2,4-dioxopyrimidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-hydroxypropylphosphonate 
• 1621174-75-1 diethyl {2-[4-((3-benzoyl-2,4-dioxopyrimidin-1-yl)methyl)-1,2,3-triazol-1-yl]acetamido}methylphosphonate 
• 1621397-44-1 tert-butyl (R)-1-(O,O-diethylphosphono)-3-{4-[(3,4-dihydro-3-benzoyl-2,4-dioxopyrimidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}propylcarbamate 
• 1621397-45-2 tert-butyl (S)-1-(O,O-diethylphosphono)-3-{4-[(3,4-dihydro-3-benzoyl-2,4-dioxopyrimidin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}propylcarbamate 

Relevant academic research and scientific papers

The synthesis, antiviral, cytostatic and cytotoxic evaluation of a new series of acyclonucleotide analogues with a 1,2,3-triazole linker

The efficient synthesis of a new series of acyclonucleotide analogues with a 1,2,3-triazole linker is described starting from diethyl azidomethyl-, 2-azidoethyl-, 3-azidopropyl-, 4-azidobutyl-, 2-azido-1-hydroxyethyl-, 3-azido-2-hydroxypropyl- and 3-azido-1-hydroxypropylphosphonates and selected alkynes under microwave irradiation. Several O,O-diethylphosphonate acyclonucleotides were transformed into the respective phosphonic acids. All compounds were evaluated in vitro for activity against a broad variety of DNA and RNA viruses and cytostatic activity against murine leukaemia L1210, human T-lymphocyte CEM and human cervix carcinoma HeLa cells. Acyclonucleotide 22e exhibited activity against both herpes simplex viruses (HSV-1, HSV-2) in HEL cell cultures (EC50 = 17 μM) and feline herpes virus (EC 50 = 24 μM) in CRFK cell cultures, while compounds 20k, 21k, 22k and 23k preferentially inhibited proliferation of human T-lymphocyte CEM cells at IC50 in the 2.8-12 μM range.

Heterocyclic nucleoside analogues: Design and synthesis of antiviral, modified nucleosides containing isoxazole heterocycles

We have designed and synthesized novel antiviral nucleoside analogues, which consist of isoxazole rings as modified sugars and nucleobases (thymine, uracil, and 5-fluorouracil) with a methylene linker between them. These compounds represent a new class of